REGISTER
Stem-Cell Islets Push Type 1 Diabetes Toward Cure
A new study from Shanghai reports another major step toward curing diabetes with regenerative islet therapy.

The latest findings not only extend Shanghai Changzheng Hospital's earlier breakthrough in curing type 2 diabetes, but also mark a major step forward toward curing type 1 diabetes.

Chinese doctors disclose the details behind a diabetes “cure”

A 45-year-old patient with type 1 diabetes was able to stop insulin completely after a single treatment, maintain stable blood glucose, and remain in a cured state for more than two years.

On February 26, the team led by Prof. Hao Yin at Shanghai Changzheng Hospital published its results in The Lancet Diabetes & Endocrinology, reporting another major advance in diabetes treatment through transplantation of stem-cell-derived regenerative islets, known as E-islets.

The study showed that all three patients with severe type 1 diabetes achieved reconstruction of islet function and autonomous glucose regulation after treatment. The same approach was also validated in children and adolescents, marking a breakthrough step for China in the effort to cure type 1 diabetes.

According to the team, the allogeneic regenerative islet injection E-islet 01, which they co-developed, has received investigational new drug approval from both Chinese and U.S. regulators for the treatment of severe type 1 diabetes. It is the first regenerative islet product in the world to enter clinical trials in both countries.

China has roughly 1 million people with type 1 diabetes. They require lifelong insulin and other glucose-lowering therapies, yet precise glucose control remains difficult and the risks of microvascular disease, macrovascular disease, and neuropathy remain high. Researchers therefore hope to replace damaged islet function with a natural regenerative islet source that can restore physiologic glucose control without constant extra medication.

The Lancet paper disclosed treatment details for three patients. The first was a 30-year-old woman, the world's first patient with type 1 diabetes to receive an autologous regenerative islet transplant. She had lived with the disease for 18 years. Despite intensive therapy, her glucose was in range only about half the time, and she experienced an average of 4.6 severe hypoglycemic episodes per week. In May 2023, the Changzheng Hospital team infused E-islets equivalent to about 1.2 million islet equivalents into her body and used a standard immunosuppressive regimen. Six months later, her C-peptide level had returned to normal, her time in range had risen to 97%, and her insulin use had dropped nearly sevenfold.

The second patient was a 45-year-old man. After receiving an allogeneic regenerative islet transplant in October 2023, his islet function gradually recovered, and his glucose control improved markedly. Nine months later, he stopped insulin completely, maintained 100% time in range, and has now remained in a cured state for more than 26 months.

The third patient was the first minor in the world to receive a regenerative islet transplant. After allogeneic E-islet transplantation plus standard-dose immunosuppression, her islet function gradually recovered, her daily time in range rose from 25% to 94%, her insulin use fell 3.5-fold, and hypoglycemic events disappeared. These results suggest that the therapy is also clinically safe and effective in children and adolescents.

Could the era of curing diabetes really be arriving?

In recent years, stem-cell-based diabetes research has advanced quickly. On May 7, 2024, Prof. Yin and collaborators reported in Cell Discovery that autologous stem-cell-derived regenerative islet transplantation had cured a patient with a 25-year history of type 2 diabetes.

On April 18, 2025, Changzheng Hospital announced that E-islet 01 had received implied approval from China's National Medical Products Administration for clinical testing, and that multiple patients with type 1 diabetes had already been successfully cured. In January this year, the U.S. Food and Drug Administration also cleared the therapy for clinical trials.

Globally, Vertex Pharmaceuticals' zimislecel is further along. In an earlier phase I/II trial, 10 patients with type 1 diabetes stopped insulin within six months of receiving zimislecel, and two others reduced insulin doses by 70% and 36%, respectively. Vertex says zimislecel has now entered a pivotal phase III trial.

It is worth noting, however, that both E-islet 01 and zimislecel are allogeneic stem-cell regenerative therapies, meaning they use someone else's stem cells. That allows advance manufacturing, but patients must take long-term anti-rejection medication after treatment. The new study also documented, for the first time worldwide, recurrence of autoimmunity after autologous regenerative islet transplantation.

For that reason, Prof. Yin said the team is now exploring more precise immunosuppressive regimens and developing broadly applicable regenerative islets with immune-evasion capability that would not require immunosuppressants, in the hope of benefiting more people with diabetes.

0
0
Loading